Brought to you by 
ObsEva closes CHF60mm Series B round
23 Nov 2015
Executive Summary
Women's health firm ObsEva SA raised CHF60mm ($58.9mm) through its Series B round. New buyers HBM Healthcare Investments, New Enterprise Associates (also joins the company's board), OrbiMed, and Rock Springs Capital invested alongside returning backers Sofinnova Ventures, Sofinnova Partners, Novo Ventures, and MS Ventures. Proceeds will fund pipeline development; just prior to the Series B, ObsEva announced that it licensed exclusive global rights (outside of Asia) to Kissei's oral GnRH antagonist KLH2109, which is in Phase II trials for endometriosis.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ObsEva closes CHF60mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice